Company Filing History:
Years Active: 2025
Title: Madlen Witt: Innovator in Ocular Treatment
Introduction
Madlen Witt is a prominent inventor based in Heidelberg, Germany. She has made significant contributions to the field of ophthalmology, particularly in the treatment of ocular neovascularization. Her innovative work has led to the development of a unique ophthalmic composition that addresses critical medical needs.
Latest Patents
Madlen Witt holds a patent for her invention titled "Compositions and methods for the treatment of ocular neovascularization." This patent describes a non-aqueous ophthalmic composition that includes particles of a protein powder preparation suspended in a liquid vehicle comprising a semifluorinated alkane. The composition features an anti-VEGF protein, specifically aflibercept or a sequence with at least 90% sequence identity to SEQ ID NO: 1. This invention is particularly suitable for treating ocular neovascularization, showcasing her commitment to advancing medical treatments.
Career Highlights
Madlen Witt is associated with Novaliq GmbH, a company dedicated to developing innovative therapies for eye diseases. Her work at Novaliq has positioned her as a key player in the field of ophthalmic research and development. With her expertise, she has contributed to the advancement of treatments that improve patient outcomes.
Collaborations
Madlen has collaborated with notable colleagues, including Claus Cursiefen and Felix Bock. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic solutions.
Conclusion
Madlen Witt's contributions to ocular treatment through her innovative patent and work at Novaliq GmbH highlight her role as a leading inventor in the field. Her dedication to improving medical treatments continues to make a significant impact on patient care.